Precision BioSciences Reports First Quarter 2022 Financial Results and Provides Business Update
- PBCAR0191, PBCAR19B and PBCAR269A Allogeneic CAR T Program Updates Planned for June 2022 - Three Wholly Owned In Vivo Gene Editing Programs Progressing Toward IND or CTA in the Next Three Years - Preclinical In Vivo Gene Editing Data for Primary Hyperoxaluria Type 1 and Chronic Hepatitis B Accep...